Literature DB >> 19822911

A 30-month prospective study on the treatment of retinoblastoma in the Gabriel Toure Teaching Hospital, Bamako, Mali.

Togo Boubacar1, Sylla Fatou, Traoré Fousseyni, Sylla Mariam, Dicko-Traoré Fatoumata, Sidibé Toumani, Diakité Abdoul-Aziz, Keïta Mamadou Marouf.   

Abstract

INTRODUCTION: Retinoblastoma is one of the most common malignant tumours among children in Africa. However, very few studies on this disease have been published, especially studies from French-speaking countries in Africa. PATIENTS AND METHODS: Prospective study over a period of 30 months from 1 January 2005 to 30 June 2007 on all cases of retinoblastoma diagnosed and treated in the Paediatric Oncology Unit of the Gabriel Touré Hospital in Bamako, Mali. Treatment was two courses of pre-operative chemotherapy (cyclophosphamide, adriamycine and vincristine), enucleation for many patients, and then two courses of adjuvant chemotherapy with the same drugs.
RESULTS: During the study period, 55 cases of retinoblastoma were treated, which represents 33.1% of all the solid tumours, coming second in frequency after lymphomas (39.7%). The mean age of the patients was 4.2 years. Boys were the most affected, with a sex ratio of 2:1. Forty-nine mothers (89.1%) and 46 fathers (83.6%) had no formal education. Thirty-seven children (67.3%) were from rural areas. Unilateral cases were predominant (49 cases (89.1%)). Ten cases (10.9%) were bilateral. Exophthalmos was the leading symptom (30 cases (54.5%)). The survival rate at 30 months was 56% with 18% lost at follow-up.
CONCLUSION: Mortality as a result of retinoblastoma remains high in our region because diagnosis is always late and it is difficult to follow-up the patients. Education of healthcare workers and raising awareness in the general population would improve the survival rate of retinoblastoma patients in Africa.

Entities:  

Mesh:

Year:  2009        PMID: 19822911     DOI: 10.1136/bjo.2009.159699

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro.

Authors:  Nahyoung G Lee; Jesse L Berry; Tom C Lee; Annie T Wang; Scott Honowitz; A Linn Murphree; Neeta Varshney; David R Hinton; Amani A Fawzi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

2.  Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation.

Authors:  Erin M Sullivan; Matthew W Wilson; Catherine A Billups; Jianrong Wu; Thomas E Merchant; Rachel C Brennan; Barrett G Haik; Barry Shulkin; Tammy M Free; Vickie Given; Carlos Rodriguez-Galindo; Ibrahim Qaddoumi
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

Review 3.  Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy.

Authors:  C L Shields; E M Fulco; J D Arias; C Alarcon; M Pellegrini; P Rishi; S Kaliki; C G Bianciotto; J A Shields
Journal:  Eye (Lond)       Date:  2012-09-21       Impact factor: 3.775

4.  In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Antonella D'Anneo; Giuseppa Augello; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Renza Vento
Journal:  Cancer Biol Ther       Date:  2013-08-12       Impact factor: 4.742

5.  Retinoblastoma in the democratic republic of congo: 20-year review from a tertiary hospital in kinshasa.

Authors:  Aimé Kazadi Lukusa; Michel Ntetani Aloni; Bertin Kadima-Tshimanga; Moïse Mvitu-Muaka; Jean Lambert Gini Ehungu; René Ngiyulu; Pépé Ekulu Mfutu; Aléine Budiongo Nzazi
Journal:  J Cancer Epidemiol       Date:  2012-04-26

6.  Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India.

Authors:  Usha Singh; Deeksha Katoch; Savleen Kaur; Mangat Ram Dogra; Deepak Bansal; Rakesh Kapoor
Journal:  Ocul Oncol Pathol       Date:  2017-07-05

7.  A 20-Year Retrospective Review of Retinoblastoma at Two Tertiary Academic Hospitals in Johannesburg, South Africa.

Authors:  Saadiah Goolam; Hemant Kana; Nicky Welsh; Linda Wainwright; Janet Poole; Ismail Mayet
Journal:  Ocul Oncol Pathol       Date:  2017-11-04

8.  Integrating stages of change models to cast new vision on interventions to improve global retinoblastoma and childhood cancer outcomes.

Authors:  Meaghann S Weaver; Christina L Heminger; Catherine G Lam
Journal:  BMC Public Health       Date:  2014-09-11       Impact factor: 3.295

9.  Retinoblastoma in a pediatric oncology reference center in Southern Brazil.

Authors:  Simone G A Selistre; Marcelo K Maestri; Patricia Santos-Silva; Lavinia Schüler-Faccini; Luis S P Guimarães; Juliana Giacomazzi; Mario C Evangelista Júnior; Patricia Ashton-Prolla
Journal:  BMC Pediatr       Date:  2016-04-03       Impact factor: 2.125

10.  Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma.

Authors:  Mehnaz Khan; Laura L Walters; Qiang Li; Dafydd G Thomas; Jason M L Miller; Qitao Zhang; Andrew P Sciallis; Yu Liu; Brian J Dlouhy; Patrice E Fort; Steven M Archer; Hakan Demirci; Yali Dou; Rajesh C Rao
Journal:  Lab Invest       Date:  2015-08-17       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.